Selatogrel Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Selatogrel comprises 8 peer-reviewed publications across 5 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including . Most recent publication: Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects., Clin Pharmacokinet, 2022.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects.
    Zenklusen I, Hsin CH, Schilling U, et al. · Clin Pharmacokinet · 2022
    PubMed: PMID 34961905 · NCT04557280
  2. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.
    Storey RF, Gurbel PA, Ten Berg J, et al. · Eur Heart J · 2021
    PubMed: PMID 31994703 · NCT03384966
  3. Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction.
    Sinnaeve P, Fahrni G, Schelfaut D, et al. · J Am Coll Cardiol · 2021
    PubMed: PMID 32439008 · NCT03487445
  4. Fourth Universal Definition of Myocardial Infarction (2018).
    Thygesen K, Alpert JS, Jaffe AS, et al. · J Am Coll Cardiol · 2019
    PubMed: PMID 30153967 · NCT04957719 (SOS-AMI)
  5. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G, Bellandi B, Valenti R, et al. · Am Heart J · 2014
    PubMed: PMID 24890542 · NCT03487445
  6. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
    Mehran R, Rao SV, Bhatt DL, et al. · Circulation · 2011
    PubMed: PMID 21670242 · NCT04957719 (SOS-AMI)
  7. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
    Jernberg T, Payne CD, Winters KJ, et al. · Eur Heart J · 2007
    PubMed: PMID 16621870 · NCT03487445
  8. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
    Gurbel PA, Bliden KP, Butler K, et al. · Circulation · 2010
    PubMed: PMID 20194878 · NCT03487445

Publications by year

2007–2022: 8 publications.

2007
1
2010
1
2011
1
2014
1
2019
1
2021
2
2022
1

Publications by journal

All Selatogrel publications (8)

2022 (1 paper)

  1. Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects.
    Zenklusen I, Hsin CH, Schilling U, et al. · Clin Pharmacokinet · 2022 · Trial result
    PubMed: PMID 34961905 · NCT04557280

2021 (2 papers)

  1. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.
    Storey RF, Gurbel PA, Ten Berg J, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 31994703 · NCT03384966
  2. Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction.
    Sinnaeve P, Fahrni G, Schelfaut D, et al. · J Am Coll Cardiol · 2021 · Derived
    PubMed: PMID 32439008 · NCT03487445

2019 (1 paper)

  1. Fourth Universal Definition of Myocardial Infarction (2018).
    Thygesen K, Alpert JS, Jaffe AS, et al. · J Am Coll Cardiol · 2019 · Background
    PubMed: PMID 30153967 · NCT04957719 (SOS-AMI)

2014 (1 paper)

  1. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G, Bellandi B, Valenti R, et al. · Am Heart J · 2014 · Background
    PubMed: PMID 24890542 · NCT03487445

2011 (1 paper)

  1. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
    Mehran R, Rao SV, Bhatt DL, et al. · Circulation · 2011 · Background
    PubMed: PMID 21670242 · NCT04957719 (SOS-AMI)

2010 (1 paper)

  1. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
    Gurbel PA, Bliden KP, Butler K, et al. · Circulation · 2010 · Background
    PubMed: PMID 20194878 · NCT03487445

2007 (1 paper)

  1. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
    Jernberg T, Payne CD, Winters KJ, et al. · Eur Heart J · 2007 · Background
    PubMed: PMID 16621870 · NCT03487445

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).